Drug intelligence / Profile preview

H-MnO2-Gel

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Intracerebral

Overview

H-MnO2-Gel is a hydrogel-based drug delivery system composed of hollow manganese dioxide (MnO2) nanoparticles embedded in a chitosan gel matrix. It is designed to treat Alzheimer's disease by effectively scavenging reactive oxygen species (ROS) and modulating the inflammatory microenvironment in the brain. By reducing oxidative stress and inflammation, H-MnO2-Gel offers a promising therapeutic approach for neurodegenerative conditions such as Alzheimer's disease[1]. The formulation leverages the antioxidant properties of MnO2 and the biocompatibility of chitosan to enhance safety and efficacy.

Other names: hollow manganese dioxide-chitosan hydrogel

Targets

Cyclic GMP–AMP synthase

Beyond the preview

Go deeper on H-MnO2-Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H-MnO2-Gel.

Explore the full profile